arrow
J

James Harnett

Regeneron
H指数:21
被引数:1,467

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comparative economic analysis of B-cell maturation antigen-targeted bispecific antibodies in triple-class exposed relapsed/refractory multiple myeloma: linvoseltamab versus teclistamab and elranatamab

三药联合方案暴露后的复发/难治性多发性骨髓瘤中B细胞成熟抗原靶向双特异性抗体的比较经济分析:linvoseltamab与teclistamab和elranatamab的比较

2026-05-010
OAAI
Indirect Comparison of Linvoseltamab vs Teclistamab for the Treatment of Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

三药耐药复发/难治性多发性骨髓瘤治疗中,林洛塞坦单抗与替西利单抗的间接比较

2025-06-220
PREAI
Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study
CANCER
IF5.1
2022-10-296
OAAI
EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer
2022-10-0120
OAAI
Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid Arthritis
2020-10-0912
OAAI